Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OctoPlus NV

Division of Dr. Reddy's Laboratories Ltd.

Latest From OctoPlus NV

Appointments: EFPIA, Celgene, AcelRx, PureTech Health, Symbiomix, CRISPR Therapeutics and Achaogen

This latest roundup includes EFPIA's appointment of Nathalie Moll to director general, CEO appointments by YposKesi and Symbiomix Therapeutics, as well as various executive appointments by PureTech Health, Arterial Capital Management and Mitra Biotech.


Appointments: Promethera, HealthTell, Baxter, Alzheon, Gilead, Arena and Ligand

This week's appointment roundup includes senior appointments by Promethera, HealthTell, Alzheon and Gilead Nordic with Baxter International, Therachon and Arena Pharmaceuticals making board appointments.


Dr. Reddy’s Chairman GV Prasad On Innovation, Biosimilars And Global Challenges: An Interview With PharmAsia News

GV Prasad, Chairman of the $2.13 billion Indian drug firm Dr. Reddy's Laboratories Ltd. is preparing to take his company from predominantly generics to super generics and untapped innovative niche products. His pet project is lower risk innovation via reverse translation by solving problems with existing molecules.

BioPharmaceutical Asia Pacific

Merck KGaA names new head of biosimilars unit

Darmstadt, Germany-headquartered Merck KGaA has named Boehringer Ingelheim's former head of biopharmaceuticals, Simon Sturge, head of its biosimilars unit – effective 1 March 2014. Mr Sturge will be based at the unit in Canton de Vaud, Switzerland and will report to Stefan Oschmann, a member of Merck's executive board responsible for the company's pharmaceutical businesses. Prior to Boehringer Ingelheim Mr Sturge was CEO of Dutch biotech-company OctoPlus.

See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
    • Vaccines
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • OctoPlus BV
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Parent & Subsidiaries
  • Dr. Reddy's Laboratories Ltd.
  • Senior Management
  • Susan Swarte, CFO
    Kenneth W Bair, SVP, R&D
    Gerben Moolhuizen, CBO
  • Contact Info
  • OctoPlus NV
    Phone: (31) (0)71 524 40 44
    Zernikedreef 12
    Leiden, 2333 CL